Analyte Comigrating with Trisialotransferrin during Capillary Zone Electrophoresis of Sera from Patients with Cancer

Clinical Chemistry

Volumn 49, Issue 11, 2003, Pages 1854-1864

  Ramdani, Brahim ^a   Nuyens, Vincent ^b   Codden, Thierry ^a   Perpete, Gael ^b,c   Colicis, Jacques ^b   Lenaerts, Anne ^a   Henry, Jean Pol ^a   Legros, Franz J ^a,b  

^a Centre Hospitalier Universitaire de Charleroi   (Belgium)

^b CHU Andre Vesale   (Belgium)

^c Haute Ecl Prov Charleroi Univ T   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CARBOHYDRATE DEFICIENT TRANSFERRIN; ORGANIC SOLVENT; PAPAIN; POLYCLONAL ANTIBODY; POLYSACCHARIDE; TRANSFERRIN;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ARTICLE; CANCER PATIENT; CAPILLARY ZONE ELECTROPHORESIS; CONTROLLED STUDY; DEVICE; DISSEMINATED CANCER; FEMALE; GLYCOSYLATION; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; ROC CURVE;

ALCOHOL DRINKING; ALCOHOLISM; ELECTROPHORESIS, CAPILLARY; FEMALE; GLYCOSYLATION; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNE SERA; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; NEOPLASMS; PROTEIN ISOFORMS; REFERENCE VALUES; ROC CURVE; TRANSFERRIN;

EID: 0242331108     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.019240     Document Type: Article

References (40)

1. Stibler H. Carbohydrate-deficient transferrin in serum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991;37:2029-37.
2. Arndt T. Carbohydrate-deficient transferrin as a marker of chronic alcohol abuse: a critical review of preanalysis, analysis, and interpretation. Clin Chem 2001;47:13-27.
3. de Jong G, van Dijk JP, van Eijk HG. The biology of transferrin. Clin Chim Acta 1990;190:1-46.
4. Landberg E, Pählsson P, Lundblad A, Arnetrop A, Jeppsson J-A. Carbohydrate composition of serum transferrin isoforms from patients with high alcohol consumption. Biochem Biophys Res Commun 1995;210:267-74.
5. Helander A, Eriksson G, Stibler H, Jeppsson J-O. Interference of transferrin isoform types with carbohydrate-deficient transferrin quantification in the identification of alcohol abuse. Clin Chem 2001;47:1225-33.
6. Legros FJ, Nuyens V, Minet E, Emonts P, Zouaoui Boujeltia K, Courbe A, et al. Carbohydrate-deficient transferrin isoforms and detection of alcohol abuse by capillary zone electrophoresis. Clin Chem 2002;48:2177-86.
7. Legros FJ, Nuyens V, Baudoux M, Zouaoui Boudjeltia K, Ruelle JL, Colicis J, et al. Use of capillary zone electrophoresis for differentiating excessive from moderate alcohol consumption. Clin Chem 2003;49:440-9.
8. Lowenfels AB. Epidemiologic studies of alcohol-related disease in the 20th century. J Epidemiol Biostat 2000;5:61-6.
9. Murawaki Y, Sugisaki H, Yuasa I, Kawasaki H. Serum carbohydrate- deficient transferrin in patients with non-alcoholic liver cirrhosis and with hepatocellular carcinoma. Clin Chim Acta 1997;259:97-108.
10. DiMartini A, Day N, Lane T, Beisler AT, Dew MA, Anton R. Carbohydrate-deficient transferrin in abstaining patients with end stage liver disease. Alcohol Clin Exp Res 2001;25:1729-33.
11. Yoshikawa K, Umetsu, K, Shinzawa H, Yuasa I, Maruyama K, Ohkura T, et al. Determination of carbohydrate-deficient transferrin separated by lectin affinity chromatography for detecting alcohol abuse. FEBS Lett 1999;458:112-6.
12. Dwek MV, Ross HA, Leathem AJ. Proteome and glycosylation mapping identifies post-translational modifications associated with aggressive breast cancer. Proteomics 2001;1:756-62.
13. Murata K, Miyoshi E, Kameyana M, Ishikawa O, Kabuto T, Sasaki Y, et al. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res 2000;6:1772-7.
14. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Blake C, Ho SK. Structures of disease-specific serum α-fetoprotein isoforms. Br J Cancer 2000;83:1330-7.
15. Poon TC, Mok TS, Chan AT, Chan CM, Leong V, Tsui SH, et al. Quantification and utility of monosialylated α-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total α-fetoprotein. Clin Chem 2002;48:1021-7.
16. Poon TCW, Yip T-T, Chan ATC, Yip C, Yip V, Mok TSK, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49:752-60.
17. Saunders JB, Aasland OJ, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction 1993;88:791-804.
18. Varki A, Kornfeld S. Structural studies of phosphorylated high mannose-type oligosaccharides. J Biol Chem 1980;255:10847-58.
19. Helander A, Fors M, Zakrisson B. Study of Axis-Shield %CDT immunoassay for quantification of carbohydrate-deficient transferrin (CDT) in serum. Alcohol Alcohol 2001;36:406-12.
20. Drahovsky D, Dunzendorfer U, Ziegenhagen G, Drahovsky M, Kellen JA. Reevaluation of C-reactive protein in cancer sera by radioimmunoassay and radial immunodiffusion. I. Diagnostic value and use in battery of conventional tumor markers. Oncology 1981;38:286-91.
21. Bergen HR, Lacey JM, O'Brien JF, Naylor S. Online single-step analysis of blood proteins: the transferrin story. Anal Biochem 2001;296:122-9.
22. Lacey JM, Bergen HR, Magera MJ, Naylor S, O'Brien JF. Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin Chem 2001;47:513-8.
23. Dennis JW. Asn-linked oligosaccharide processing and malignant potential. Cancer Surv 1988;7:573-95.
24. Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999;20:362-71.
25. Couldrey C, Green JE. Metastases: the glycan connection. Breast Cancer Res 2000;2:321-3.
26. Yamamoto H, Swoger J, Greene S, Saito T, Hurh J, Sweeley C, et al. β1,6-N-Acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity. Cancer Res 2000;60:134-42.
27. Ho JJL, Cheng S, Kim YS. Access to peptide regions of a surface mucin (PMC1) is reduced by sialic acids. Biochem Biophys Res Commun 1995;210:866-73.
28. Lanz C, Kuhn M, Bortolotti F, Tagliaro F, Thormann W. Evaluation and optimization of capillary zone electrophoresis with different dynamic capillary coatings for the determination of carbohydrate-deficient transferrin in human serum. J Chromatogr A 2002;979:43-57.
29. Karamanos NK, Hjefrpe A. High-performance capillary electrophoresis analysis of hyaluronan in effusions from malignant mesothelioma. J Chromatogr B 1997;697:277-81.
30. Lokeswarth VN, Rubinowicz D, Scroeder L, Forgaces E, Minna JD, Block NL, et al. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001;276:11922-32.
31. Trowbridge JM, Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 2002;12:117-25.
32. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2002;2:521-8.
33. Mao W, Thanaviroon C, Lindhart RJ. Capillary electrophoresis for the analysis of glycosaminoglycans and glycosaminoglycan-derived oligosaccharides. Biomed Chromatogr 2002;16:77-94.
34. Neususs C, Pelzing M, Macht M. A robust approach for the analysis of peptides in the low femtomole range by capillary electrophoresis-tandem mass spectrometry. Electrophoresis 2002;23:3149-59.
35. Beck JR, Shultz EK. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986;110:13-20.
36. Panesar NS, Li CY, Rogers MS. Are thyroid hormones or hCG responsible for hyperemesis gravidarum? A matched paired study in pregnant Chinese women. Acta Obstet Gynecol Scand 2001;80:519-24.
37. Pham-Huy A, Leonard M, Lepage N, Halton J, Filler G. Measuring glomerular filtration rate with cystatin C and β-trace protein in children with spina bifida. J Urol 2003;169:231:2-5.
38. den Ouden M, Ubachs JM, Stoot JE, van Wersch JW. Thrombinantithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumours. Scand J Clin Lab Invest 1998;58:555-9.
39. Pokorny RM, Hunt L, Galandiuk S. What's new with tumor markers for colorectal cancer? Dig Surg 2000;17:209-15.
40. Johnson PJ. A framework for the molecular classification of circulating tumor markers. Ann N Y Acad Sci 2001:945:8-21.